Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Case study – Pharmacological models to assess the role of tryptophan-metabolizing enzymes in cancer Oncolines®2024-11-19T12:03:15+01:00
Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin Case study – Synergistic interaction of olaparib and cisplatin Oncolines®2024-11-19T13:41:57+01:00
Case study – TTK patient stratification marker Case study – TTK patient stratification marker Case study – TTK patient stratification marker Oncolines®2024-11-19T12:51:07+01:00
Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Case study – Arginase-1 Inhibitors Oncolines®2024-11-19T13:29:24+01:00
Case study – MEK inhibitor Case study – MEK inhibitor Case study – MEK inhibitor Oncolines®2024-11-19T12:54:57+01:00
Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Case study – Characterization of TTK Inhibitors Oncolines®2024-11-19T13:34:48+01:00
Case study – Kadcyla® Case study – Kadcyla® Case study – Kadcyla® Oncolines®2024-11-19T12:57:31+01:00
Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Case study – BTK Inhibitor ibrutinib Oncolines®2024-11-19T13:18:25+01:00
